Stockscreener 앱 받기
1.80
4.26%
-0.08
시간 외 거래:
1.85
0.05
+2.78%
전일 마감가:
$1.88
열려 있는:
$1.89
하루 거래량:
3.70M
Relative Volume:
0.81
시가총액:
$285.07M
수익:
-
순이익/손실:
$-110.78M
주가수익비율:
-1.6822
EPS:
-1.07
순현금흐름:
$-75.59M
1주 성능:
+3.15%
1개월 성능:
-22.75%
6개월 성능:
-52.00%
1년 성능:
-72.22%
1일 변동 폭
$1.79
$1.9399
1주일 범위
$1.65
$2.05
52주 변동 폭
$1.15
$7.48
Humacyte Inc Stock (HUMA) Company Profile
명칭
Humacyte Inc
전화
919-313-9633
주소
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
HUMA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
1.80 | 297.74M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.88 | 100.71B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.87 | 58.84B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.91 | 61.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
661.32 | 40.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
319.32 | 38.20B | 3.81B | -644.79M | -669.77M | -6.24 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-14 | 재개 | H.C. Wainwright | Buy |
| 2024-12-20 | 재확인 | H.C. Wainwright | Buy |
| 2023-12-11 | 개시 | H.C. Wainwright | Buy |
| 2023-08-14 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2023-06-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-05-16 | 다운그레이드 | Piper Sandler | Overweight → Underweight |
| 2021-10-29 | 개시 | Cowen | Outperform |
| 2021-09-24 | 개시 | Oppenheimer | Outperform |
| 2021-09-22 | 개시 | BTIG Research | Buy |
| 2021-09-16 | 개시 | Piper Sandler | Overweight |
모두보기
Humacyte Inc 주식(HUMA)의 최신 뉴스
Humacyte Requests to Dismiss Class Action Filed by Investors - TradingView
Will Humacyte Inc. stock hit new highs in YEARNew Guidance & Daily Profit Focused Screening - thegnnews.com
Investors Hope for Bounce in Humacyte Inc. Equity Warrant After SelloffQuarterly Profit Review & Weekly Watchlist for Hot Stocks - metal.it
Humacyte Inc. Hits Oversold Level on RSI IndicatorAI Driven Entry Signal Forecast - beatles.ru
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 17, 2025 in Humacyte, Inc. LawsuitHUMA - ACCESS Newswire
Humacyte Inc. Equity Warrant’s volatility index tracking explainedJuly 2025 Review & Technical Pattern Recognition Alerts - Newser
Risk adjusted return profile for Humacyte Inc. analyzedWeekly Stock Recap & Target Return Focused Picks - Newser
Detecting price anomalies in Humacyte Inc. Equity Warrant with AIJuly 2025 Setups & High Accuracy Investment Signals - Newser
Heatmap analysis for Humacyte Inc. and competitorsJuly 2025 Reactions & Consistent Profit Trade Alerts - Newser
How to track smart money flows in Humacyte Inc.July 2025 Breakouts & Expert Verified Stock Movement Alerts - Newser
What technical models suggest about Humacyte Inc. Equity Warrant’s comeback2025 Market Outlook & Daily Profit Maximizing Trade Tips - Newser
Humacyte Inc. stock volume spike explainedJuly 2025 Review & Weekly Stock Performance Updates - Newser
Can machine learning forecast Humacyte Inc. recoveryPortfolio Return Summary & Daily Profit Focused Screening - Newser
Technical Models Suggest Humacyte Inc. Equity Warrant May Rebound SoonJuly 2025 Spike Watch & Long-Term Capital Growth Strategies - sundaytimes.kr
Humacyte Inc. Equity Warrant Could See a Relief Rally From SupportWeekly Loss Report & AI Forecast for Swing Trade Picks - beatles.ru
How to escape a deep drawdown in Humacyte Inc.Weekly Investment Report & Verified Stock Trade Ideas - Newser
How to build a custom watchlist for Humacyte Inc. Equity WarrantRate Hike & AI Enhanced Trading Alerts - Newser
Will Humacyte Inc. outperform the marketTreasury Yields & Technical Analysis for Trade Confirmation - Newser
Is Humacyte Inc. Equity Warrant stock poised for growth2025 Earnings Impact & Weekly High Potential Stock Alerts - Newser
Is Humacyte Inc. a turnaround storyQuarterly Portfolio Report & Fast Exit and Entry Trade Guides - mustnews.co.kr
Real time breakdown of Humacyte Inc. stock performance2025 Bull vs Bear & Verified Entry Point Signals - Newser
News impact scoring models applied to Humacyte Inc.Portfolio Value Summary & High Yield Stock Recommendations - Newser
Exit strategy if you’re trapped in Humacyte Inc. Equity Warrant2025 Support & Resistance & Risk Controlled Swing Alerts - Newser
Humacyte Reports Q2 2025 Earnings and Market Expansion - TipRanks
MACD Cross Could Confirm Trend in Humacyte Inc.2025 Technical Patterns & Verified Short-Term Trading Plans - newsyoung.net
Will a bounce in Humacyte Inc. Equity Warrant offer an exit2025 Year in Review & Reliable Volume Spike Trade Alerts - Newser
Will Humacyte Inc. outperform during market ralliesQuarterly Portfolio Summary & Fast Gaining Stock Reports - classian.co.kr
Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors - MSN
Earnings call transcript: Humacyte Q2 2025 misses EPS and revenue targets - Investing.com Australia
Trading Bots Trigger Alerts on Humacyte Inc. ActivityJuly 2025 Recap & Free High Return Stock Watch Alerts - metal.it
A Quick Look at Today's Ratings for Humacyte(HUMA.US), With a Forecast Between $3 to $14 - 富途牛牛
Humacyte: Cash Burn And A Glacial Launch Overshadow VAC Progress (NASDAQ:HUMA) - Seeking Alpha
Humacyte stock price target lowered to $3.50 at TD Cowen on mixed outlook - Investing.com Canada
Humacyte stock rating reiterated at Buy by Benchmark despite revenue miss - Investing.com Canada
Humacyte, Inc. (NASDAQ:HUMA) Q2 2025 Earnings Call Transcript - Insider Monkey
H.C. Wainwright lowers Humacyte stock price target to $3 on weak sales - Investing.com Canada
Analysts Expect Breakeven For Humacyte, Inc. (NASDAQ:HUMA) Before Long - simplywall.st
Humacyte targets over 200 hospital access points for Symvess as VAC approvals surge and cost cuts extend cash runway - MSN
Humacyte Inc (HUMA) Q2 2025 Earnings Call Highlights: Navigating Challenges and Celebrating ... By GuruFocus - Investing.com Canada
Humacyte Inc Navigates Challenges, Celebrates Milestones in Q2 2025 Earnings Call Highlights - AInvest
Humacyte Reports Q2 Revenue Miss, Symvess Shows Progress in Hospital Access and Sales - AInvest
Humacyte Missed Revenue Forecasts But Expanded Symvess Access - Finimize
Humacyte Posts Q2 Revenue Miss - AOL.com
Humacyte: D. Boral Capital Maintains Buy, PT Raised to $25 from $20. - AInvest
Humacyte, Inc. shares fall 31.49% intraday after reporting Q2 revenue of $301,000, far below analyst expectations of $1 million. - AInvest
Humacyte stock price target lowered to $7 at BTIG on mixed Q2 results - Investing.com Canada
Humacyte's 2025 Q2 Earnings Call: Unpacking Key Contradictions on Sales, CMS Impact, and FDA Interactions - AInvest
Sitryx gets back rights to drug from Lilly deal; Humacyte is cutting costs - Endpoints News
Humacyte Plunges 30% on Intraday Chaos: What's Fueling the Selloff? - AInvest
Humacyte Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Transcript : Humacyte, Inc., Q2 2025 Earnings Call, Aug 11, 2025 - MarketScreener
Humacyte Inc (HUMA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.18%
자본화:
|
볼륨(24시간):